2 FTSE 100 stocks I’d buy in February and 1 I’d sell

Here are some of the stocks I’m buying and selling this month.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Every investor loves dividends. They’re the bread and butter of investing. Studies have shown that if you’re not investing with dividends in mind, you stand no chance of matching the market’s returns as around 50% of these come from reinvested dividends. 

That’s why I’m always hunting out the best dividend stocks and trying to avoid the worst, those dividend stocks that are clearly pursuing an unsustainable dividend policy.

Two top dividend picks 

BP (LSE: BP) and GlaxoSmithKline (LSE: GSK) are two dividend champions that look extremely attractive right now. Shares in these two companies both offer a dividend yield of 5% or more, and as we head into 2017, the outlook for both companies is improving.

This time last year, the price of Brent crude oil was around $41 a barrel. Today, the price is more than 25% higher at $54 a barrel, which is great news for BP. Over the past year, the company has been cutting costs to deal with the low oil price environment, and over the next 12 months, these actions should begin to pay off. 

Indeed, during 2017 City analysts expect the company’s earnings per share to grow by 153% and further earnings per share growth of 19% is pencilled-in for 2018. Based on these figures, the shares are trading at a 2017 forward P/E of 14.9 and support a dividend yield of 6.6%. 

Like BP, analysts are predicting strong earnings per share growth for Glaxo during 2017. Growth of 11% is pencilled-in for the year taking earnings to 112p, the highest level since 2012. Based on these estimates the shares are trading at a forward P/E of 14 and support a dividend yield of 5.2%. By 2017, Glaxo’s dividend payout will be covered 1.5 times by earnings per share.

One stock to avoid 

In comparison to Glaxo and BP, EasyJet (LSE: EZJ) looks to me to be a company to avoid during 2017. EasyJet’s advantage over its peers used to be the carrier’s low-cost model. However, over the past few years, this economic benefit has disappeared. 

As a result, City analysts are predicting a 28% decline in earnings per share for the fiscal year to 30 September 2017. These declines follow a 22% fall in earnings per share for 2016. For the year ending 30 September 2017, City analysts expect EasyJet report a pre-tax profit of £385m and earnings per share of 78p. For some comparison, two years ago EasyJet reported a record pre-tax profit of £686m and earnings per share of 139p. 

Even though the company’s dividend yield of 5.7%, is covered twice by earnings per share at present, this payout could come under pressure if earnings continue to decline. Shares in EasyJet currently trade at a forward P/E of 12.2, which looks appropriate considering the group’s rapidly declining profits. All in all, considering EasyJet’s flagging growth it may be best to avoid the company for the time being.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended BP. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Dividend Shares

3 crucial factors for building my passive income

Ken Hall wants to build a passive income that can set him up for years to come. Here are three…

Read more »

Man smiling and working on laptop
Investing Articles

£20,000 in savings? Here’s how Stocks and Shares ISA investors could target a near-£2,000 monthly income

Investing a lump sum in this investment trust could help Stocks and Shares ISA investors make mammoth returns, says Royston…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

Surprise! This monopoly stock has taken over my Stocks and Shares ISA (again)

Our writer has a (nice) dilemma in his Stocks and Shares ISA portfolio after one incredible growth stock rocketed higher…

Read more »

Investing Articles

10.5% yield – but could the abrdn share price get even cheaper?

Christopher Ruane sees some things to like about the current abrdn share price. But will that be enough to overcome…

Read more »

Investing Articles

£9,000 to invest? These 3 high-yield shares could deliver a £657 annual passive income

The high yields on these dividend shares sail sit well above the FTSE 100 average of 3.6%. Here's why I…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

I’ve got £2k and I’m on the hunt for cheap shares to buy in December

Harvey Jones finally has some cash in his trading account and is hunting for cheap shares to buy next month.…

Read more »

Investing Articles

Down 25% with a 4.32% yield and P/E of 8.6! Is this my best second income stock or worst?

Harvey Jones bought GSK shares hoping to bag a solid second income stream while nailing down steady share price growth…

Read more »

Investing Articles

Here’s how the Legal & General dividend yield could ultimately hit 15%!

The Legal & General dividend yield is already among the best of any FTSE 100 share. Christopher Ruane explores some…

Read more »